Skip to search formSkip to main contentSkip to account menu

LY 163892

Known as: LY-163892, LY163892 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

loracarbef

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia
2005
2005
Susceptibility of new β-lactams to the expanded-spectrum β-lactamase CTX-1
SummaryForty-three clinical isolates of enterobacteria were selected for the production of the new plasmid-mediated expanded… 
1995
1995
Sputum and serum pharmacokinetics of loracarbef (LY163892) in patients with bronchial sepsis.
1992
1992
Bactericidal Titers ofLoracarbef (LY163892) inSerumandKilling RatesinVolunteers Receiving 400versus 200Milligrams
Inarandomized crossover trial, sixvolunteers received 200-and400-mg doses ofloracarbef (LY163892), aneworalcephalosporin. Mean… 
1989
1989
Bactericidal activity of LY-163892, a new cephalosporin, against beta-lactamase-producing strains of Haemophilus influenzae compared with amoxicillin-clavulanic acid
The rate of bactericidal activity of a new cephalosporin, LY-163892, was compared with that of the combination of amoxicillin and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)